Related references
Note: Only part of the references are listed.Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009
Jan Sjoberg et al.
BLOOD (2012)
A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era
Andrew M. Evens et al.
BLOOD (2012)
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Michelle A. Fanale et al.
CLINICAL CANCER RESEARCH (2012)
Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma
Kelley V. Foyil et al.
LEUKEMIA & LYMPHOMA (2012)
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
Todd A. Fehniger et al.
BLOOD (2011)
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
Werner Kempf et al.
BLOOD (2011)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L. Piekarz et al.
BLOOD (2011)
Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)
Claire E. Dearden et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
OX40 and CD30 signals in CD4+ T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T-cell memory but not effector function
David R. Withers et al.
IMMUNOLOGICAL REVIEWS (2011)
Abrogation of CD30 and OX40 signals prevents autoimmune disease in FoxP3-deficient mice
Fabrina M. Gaspal et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
Olaf Merkel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism
K. A. Blum et al.
ANNALS OF ONCOLOGY (2010)
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
Francesco d'Amore et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism
Daniela Buglio et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Upcoming Diagnostic and Therapeutic Developments in Classical Hodgkin's Lymphoma
Kristie A. Blum
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma
Pina M. Cardarelli et al.
CLINICAL CANCER RESEARCH (2009)
A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders
Madeleine Duvic et al.
CLINICAL CANCER RESEARCH (2009)
Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients
Hermann Brenner et al.
BLOOD (2008)
ALK-anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:: report from the International Peripheral T-Cell Lymphoma Project
Kerry J. Savage et al.
BLOOD (2008)
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
Ezogelin Oflazoglu et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
A Novel Role of CD30L/CD30 Signaling by T-T Cell Interaction in Th1 Response against Mycobacterial Infection
Ce Tang et al.
JOURNAL OF IMMUNOLOGY (2008)
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Nancy L. Bartlett et al.
BLOOD (2008)
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
Navneet S. Majhail et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Deciphering CD30 ligand biology and its role in humoral immunity
Mary K. Kennedy et al.
IMMUNOLOGY (2006)
Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse
A Sureda et al.
ANNALS OF ONCOLOGY (2005)
Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab
O Lindén
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Critical roles of CD30/CD30L interactions in murine autoimmune diabetes
S Chakrabarty et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2003)
cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
JA Francisco et al.
BLOOD (2003)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Inhibition of type 1 cytokine-mediated inflammation by a soluble CD30 homologue encoded by ectromelia (mousepox) virus
M Saraiva et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism
H Harlin et al.
JOURNAL OF IMMUNOLOGY (2002)
The TNF receptor family member CD30 is not essential for negative selection
AL DeYoung et al.
JOURNAL OF IMMUNOLOGY (2000)
Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene
EJ Croager et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
